Professor Paul Workman, former Chief Executive and President of The Institute of Cancer Research, London, from 2014 to 2021, has been elected as a Fellow of the American Association for the Advancement of Science (AAAS), one of the most distinguished honours in the scientific community.

A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial.

Members of the ICR’s Discovery Club gathered at The Royal Society to hear about our new five-year research strategy and to mark two years since the opening of our pioneering Centre for Cancer Drug Discovery.